Disruption of the PD-1-PD-L1 interaction increases B-cell activation, proliferation and cytokine production, which might be why anti-PD-1/PD-L1 inhibitors can exhibit effectiveness in some tumours with few PD-1+ T cells (44). The gene discussed is CD274; the disease is neoplasm.